Neurodegenerative disease management最新文献_第9页

Effects of an low carbohydrate/healthy fat/ketogenic diet on biomarkers of health and symptoms, anxiety and depression in Parkinson's disease: a pilot study. 低碳水化合物/健康脂肪/生酮饮食对帕金森病健康和症状、焦虑和抑郁生物标志物的影响:一项初步研究

IF 2.6

Neurodegenerative disease management Pub Date : 2022-04-01 Epub Date: 2022-02-18 DOI: 10.2217/nmt-2021-0033

Melanie M Tidman, Dawn White, Timothy White

引用次数: 11

Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials. 左旋多巴诱发的运动障碍：正在进行的临床试验简评。

IF 2.6

Neurodegenerative disease management Pub Date : 2022-04-01 Epub Date: 2021-12-23 DOI: 10.2217/nmt-2021-0051

Philippe Huot, Woojin Kang, Esther Kim, Dominique Bédard, Sébastien Belliveau, Imane Frouni, Cynthia Kwan

引用次数: 0

Evaluating binary classifiers: extending the Efficiency Index 评估二元分类器：扩展效率指数

IF 2.6

Neurodegenerative disease management Pub Date : 2022-02-04 DOI: 10.1101/2022.02.02.22270139

A. Larner

引用次数: 1

Evidence base for investigative and therapeutic modalities in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. 慢性炎症性脱髓鞘性多神经病变和多灶性运动神经病变的调查和治疗方法的证据基础。

IF 2.6

Neurodegenerative disease management Pub Date : 2022-02-01 Epub Date: 2022-01-10 DOI: 10.2217/nmt-2021-0015

Hendrik Stephan Goedee, Yusuf A Rajabally

{"title":"Evidence base for investigative and therapeutic modalities in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.","authors":"Hendrik Stephan Goedee, Yusuf A Rajabally","doi":"10.2217/nmt-2021-0015","DOIUrl":"https://doi.org/10.2217/nmt-2021-0015","url":null,"abstract":"Chronic inflammatory demyelinating polyneuropathy, its variants and multifocal motor neuropathy belong to a spectrum of peripheral nerve disorders with complex dysimmune disease mechanisms. Awareness of the unique clinical phenotypes but also heterogeneity between patients is vital to arrive at early suspicion and ordering appropriate tests. This includes requirements for optimal electrodiagnostic protocol, aimed to capture sufficient electrophysiologic evidence for relevant abnormalities, a case-based approach on the eventual need to further expand the diagnostic armamentarium and correct reading of their results. Considerable phenotypical variation, diverse combinations of abnormalities found on diagnostic tests and heterogeneity in disease course and treatment response, all contribute to widespread differences in success rates on timely diagnosis and optimal treatment. We aim to provide a practical overview and guidance on relevant diagnostic and management strategies, including pitfalls and present a summary of the relevant novel developments in this field.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"12 1","pages":"35-47"},"PeriodicalIF":2.6,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39665374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Family planning in people with multiple sclerosis: a plain language summary. 多发性硬化症患者的计划生育:简单的语言总结。

IF 2.3

Neurodegenerative disease management Pub Date : 2022-02-01 Epub Date: 2022-02-03 DOI: 10.2217/nmt-2021-0045

Simona Bonavita, Luigi Lavorgna, Hilary Worton, Dominic Jack

{"title":"Family planning in people with multiple sclerosis: a plain language summary.","authors":"Simona Bonavita, Luigi Lavorgna, Hilary Worton, Dominic Jack","doi":"10.2217/nmt-2021-0045","DOIUrl":"10.2217/nmt-2021-0045","url":null,"abstract":"What is this summary about?: This is a plain language summary of an article originally published in the journal Frontiers in Neurology. People with multiple sclerosis (often shortened to MS) may have concerns about pregnancy and fertility. To understand more about these concerns, 332 people with MS in the USA, UK, France, Germany, Italy, and Spain took a survey with questions about how they made family planning decisions.What were the results?: Most of the survey participants (around 82%) were women. The survey found that people with MS were less likely to have children than people without MS. Over half (56%) of people with MS said the disease impacted their family planning decisions in some way, almost one quarter (22%) significantly changed their plans for the timing of their pregnancy or number of children, and 14% decided against having children. For almost 4 out of 5 (81%) people with MS the main source of family planning information was healthcare professionals.What do the results of the study mean?: Overall, MS significantly impacted patients' decisions about family planning.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"12 1","pages":"9-14"},"PeriodicalIF":2.3,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39883518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum. 有待纠正。

IF 2.6

Neurodegenerative disease management Pub Date : 2022-02-01 Epub Date: 2022-01-10 DOI: 10.2217/nmt-2020-0021c1

引用次数: 0

GOCOVRI^® (amantadine) extended-release capsules in Parkinson's disease. GOCOVRI®(金刚烷胺)缓释胶囊治疗帕金森病

IF 2.6

Neurodegenerative disease management Pub Date : 2022-02-01 Epub Date: 2021-12-17 DOI: 10.2217/nmt-2021-0028

Thomas Müller

引用次数: 2

COVID-19-associated encephalitis or Creutzfeldt-Jakob disease: a case report. covid -19相关脑炎或克雅氏病1例报告

IF 2.6

Neurodegenerative disease management Pub Date : 2022-02-01 Epub Date: 2021-12-02 DOI: 10.2217/nmt-2021-0025

Gooya Tayyebi, Seyed Kazem Malakouti, Behnam Shariati, Leila Kamalzadeh

引用次数: 8

Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. 多发性硬化症患者在使用克拉德滨片治疗的第一年早期发生的副作用:简单的语言总结。

IF 2.3

Neurodegenerative disease management Pub Date : 2022-02-01 Epub Date: 2022-01-12 DOI: 10.2217/nmt-2021-0041

Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson, Thomas P Leist

{"title":"Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.","authors":"Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson, Thomas P Leist","doi":"10.2217/nmt-2021-0041","DOIUrl":"10.2217/nmt-2021-0041","url":null,"abstract":"People with multiple sclerosis (also shortened to MS) may have difficulties staying on treatment due to side effects. Cladribine tablets, approved for treating relapsing forms of MS, are given by mouth for four short periods over two years. The benefit of convenient dosing may be lost if side effects prevent people with MS from finishing their treatment. This is the summary of a study that examined side effects from cladribine tablets treatment in the first 12 weeks of two clinical studies called CLARITY and ORACLE-MS. Overall, 34.7% of participants who took cladribine tablets experienced drug-related side effects compared to 23.2% of participants who took placebo. Most side effects were mild and were seen in 54.8% of participants taking cladribine tablets and 59.1% taking the placebo. A low number of participants discontinued treatment due to side effects (1.6% of participants who took cladribine tablets; 1.4% of participants who took placebo). The researchers concluded that cladribine tablets are well-tolerated and people with MS are likely to complete the full treatment course. ClinicalTrials.gov NCT numbers: CLARITY study - NCT00213135 and ORACLE-MS study - NCT00725985.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"12 1","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39813239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. MN-166(布司特)在肌萎缩性侧索硬化症的IIb/III期研究:COMBAT-ALS研究设计。

IF 2.6

Neurodegenerative disease management Pub Date : 2021-12-01 Epub Date: 2021-11-24 DOI: 10.2217/nmt-2021-0042

Björn Oskarsson, Nicholas Maragakis, Richard S Bedlack, Namita Goyal, Jenny A Meyer, Angela Genge, Cynthia Bodkin, Samuel Maiser, Nathan Staff, Lorne Zinman, Nicholas Olney, John Turnbull, Benjamin Rix Brooks, Emelia Klonowski, Malath Makhay, Seiichi Yasui, Kazuko Matsuda

{"title":"MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.","authors":"Björn Oskarsson, Nicholas Maragakis, Richard S Bedlack, Namita Goyal, Jenny A Meyer, Angela Genge, Cynthia Bodkin, Samuel Maiser, Nathan Staff, Lorne Zinman, Nicholas Olney, John Turnbull, Benjamin Rix Brooks, Emelia Klonowski, Malath Makhay, Seiichi Yasui, Kazuko Matsuda","doi":"10.2217/nmt-2021-0042","DOIUrl":"https://doi.org/10.2217/nmt-2021-0042","url":null,"abstract":"Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with motor neuron loss as a defining feature. Despite significant effort, therapeutic breakthroughs have been modest. MN-166 (ibudilast) has demonstrated neuroprotective action by various mechanisms: inhibition of proinflammatory cytokines and macrophage migration inhibitory factor, phosphodiesterase inhibition, and attenuation of glial cell activation in models of ALS. Early-phase studies suggest that MN-166 may improve survival outcomes and slow disease progression in patients with ALS. This article describes the rationale and design of COMBAT-ALS, an ongoing randomized, double-blind, placebo-controlled, multicenter Phase IIb/III study in ALS. This study is designed to evaluate the pharmacokinetics, safety and tolerability and assess the efficacy of MN-166 on function, muscle strength, quality of life and survival in ALS.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"11 6","pages":"431-443"},"PeriodicalIF":2.6,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39765803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13